Although clinical administration of IFNα2 increased the number of low-dose mucosal inoculations needed for breakthrough SIV infection in rhesus macaques, once the infection was established, lower CD4 T cell counts were observed in IFNα2-treated monkeys relative to untreated controls [23]. This evidence concerns the gene IFNA2 and infection.